Premium
Elimination of Latently HIV‐1‐Infected Cells by Lymphoblasts Armed with Bifunctional Antibody
Author(s) -
Yin Shuping,
Okada Noriko,
Okada Hidechika
Publication year - 2001
Publication title -
microbiology and immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.664
H-Index - 70
eISSN - 1348-0421
pISSN - 0385-5600
DOI - 10.1111/j.1348-0421.2001.tb01266.x
Subject(s) - monoclonal antibody , lymphoblast , virology , biology , antibody , virus , cytolysis , epitope , microbiology and biotechnology , cell culture , immunology , in vitro , cytotoxic t cell , biochemistry , genetics
The Fab′ fragment of a monoclonal antibody (mAb) to CD3 and the F(ab′) 2 fragment of a mAb to human immunodeficiency virus 1 (HIV‐1) gp41 were combined to generate a bifunctional antibody (BFA). The mAb to gp41 (IV1‐4G6) has previously been shown to react with a number of HIV‐1 strains and T‐lymphoblastoid cells (TLBC) armed with the BFA (BFA‐TLBC) effectively inhibited HIV‐1 in primarily cultured lymphoblasts infected with the clinically isolated virus which was reactive to the mAb. Although BFA‐TLBC could not cause cytolysis of 51 Cr‐labeled latently infected cells (OM‐10.1) in 6 hr incubation, cocultivation of OM‐10.1 cells with BFA‐TLBC for 3 days or more eliminated the latently infected cells making the cells susceptible to BFA‐TLBC. Therefore, BFA‐TLBC may be beneficial for HIV‐infected patients in eradicating latently infected cells which can not be eliminated even with highly active antiretroviral therapy (HAART).